BTK inhibitors are a class of drugs designed to selectively target and inhibit the activity of the BTK enzyme. These inhibitors bind to the active site of BTK, preventing its activation and subsequent signaling through the BCR pathway. By blocking BTK, these drugs aim to halt the proliferation of malignant B-cells and modulate autoimmune responses.
